Citadel Advisors
NXTC icon

Citadel Advisors’s NextCure NXTC Stock Holding History

Citadel Advisors’s Portfolio NXTC Stock Details NXTC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-15,292
Closed -$161K – 14499
2026
Q1 		$161K Buy
+15,292
New +$187K ﹤0.01% 11623
2025
Q3 		– Sell
-4,904
Closed -$27.1K – 13704
2025
Q2 		$27.1K Sell
4,904
-2,650
-35% -$14.2K ﹤0.01% 12023
2025
Q1 		$43.5K Buy
7,554
+997
+15% +$8.79K ﹤0.01% 12445
2024
Q4 		$60.7K Buy
6,557
+1,894
+41% +$27.9K ﹤0.01% 12171
2024
Q3 		$76.7K Sell
4,663
-19,425
-81% -$357K ﹤0.01% 11459
2024
Q2 		$460K Buy
24,088
+3,632
+18% +$70.6K ﹤0.01% 8226
2024
Q1 		$547K Sell
20,456
-10,865
-35% -$187K ﹤0.01% 8180
2023
Q4 		$428K Sell
31,321
-5,230
-14% -$75.8K ﹤0.01% 8432
2023
Q3 		$566K Buy
36,551
+3,779
+12% +$72.1K ﹤0.01% 7798
2023
Q2 		$708K Sell
32,772
-7,215
-18% -$142K ﹤0.01% 7175
2023
Q1 		$710K Sell
39,987
-3,527
-8% -$67.9K ﹤0.01% 7535
2022
Q4 		$736K Buy
43,514
+4,006
+10% +$92.2K ﹤0.01% 7426
2022
Q3 		$1.3M Buy
39,508
+6,727
+21% +$343K ﹤0.01% 6434
2022
Q2 		$1.85M Buy
32,781
+282
+0.9% +$14.7K ﹤0.01% 5693
2022
Q1 		$1.9M Sell
32,499
-304
-0.9% -$19K ﹤0.01% 6209
2021
Q4 		$2.36M Sell
32,803
-257
-0.8% -$21.5K ﹤0.01% 5864
2021
Q3 		$2.67M Sell
33,060
-26,242
-44% -$2.3M ﹤0.01% 5638
2021
Q2 		$5.71M Sell
59,302
-29,066
-33% -$2.97M ﹤0.01% 4149
2021
Q1 		$10.6M Sell
88,368
-1,119
-1% -$162K ﹤0.01% 2881
2020
Q4 		$11.7M Sell
89,487
-268
-0.3% -$34.6K ﹤0.01% 2436
2020
Q3 		$9.48M Buy
89,755
+85,192
+1,867% +$10.5M ﹤0.01% 2349
2020
Q2 		$1.17M Sell
4,563
-2,397
-34% -$913K ﹤0.01% 5538
2020
Q1 		$3.1M Sell
6,960
-59,516
-90% -$31.8M ﹤0.01% 3412
2019
Q4 		$44.9M Sell
66,476
-11,987
-15% -$6.01M 0.02% 837
2019
Q3 		$29M Sell
78,463
-12,686
-14% -$4.13M 0.01% 1152
2019
Q2 		$16.4M Buy
+91,149
New +$18.9M 0.01% 1620

Other funds holding NXTC

IC
Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $1.93B AUM 134.74% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.6B AUM 109.3% 1-Year Est. Return
SCM
Squadron Capital Management Westmont, Illinois $322M AUM
VA
Verdad Advisers Boston, Massachusetts $104M AUM
P
Pfizer New York $170M AUM 191.09% 1-Year Est. Return

Citadel Advisors's NXTC Position: Q2 2026 in Review

Citadel Advisors sold out of NextCure (NXTC) in Q2 2026, closing a stake of 15,292 shares — an estimated $161K sold.

Citadel Advisors first reported a position in NXTC in Q2 2019 and held it in 26 quarters. The position peaked at $44.9M in Q4 2019. 30 funds tracked by Wall St. Rank hold NXTC as of Q2 2026.

  • Citadel Advisors reported no remaining NextCure position as of Q2 2026 after selling out during the quarter.
  • Citadel Advisors sold 15,292 NextCure shares in Q2 2026, an estimated $161K.
  • Citadel Advisors first reported a position in NextCure in Q2 2019 and held it in 26 quarters.
  • Citadel Advisors's NextCure position peaked at $44.9M in Q4 2019.
  • 30 funds tracked by Wall St. Rank held NextCure as of Q2 2026.

Based on Citadel Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.